Insulin-like growth factor binding protein-1 as a marker of the metabolic syndrome - A study in borderline hypertension

Blood Pressure

Volumn 7, Issue 2, 1998, Pages 89-95

  Lemne, Carola ^a   Brismar, Kerstin ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Ambulatory blood pressure; Borderline hypertension; Insulin resistance; Insulin like growth factor; Insulin like growth factor binding protein; Left ventricular hypertrophy

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANTHROPOMETRY; ARTICLE; BORDERLINE HYPERTENSION; CONTROLLED STUDY; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; HUMANS; HYPERTENSION; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; LIPOPROTEINS; MALE; MIDDLE AGED; SYNDROME;

EID: 0031808690     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Langford KS, Miell JP. The insulin-like growth factor/ binding protein axis: physiology, pathophysiology and therapeutic manipulation. Eur J Clin Invest 1993; 3: 98-100.
2. Wahlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 1992; 19: 25-32.
3. Andronico G, Mangano MT, Nardi E, Mulè ??, Piazza G, Cerasola G. Insulin-like growth factor I and sodium-lithium countertransport in essential hypertension and in hypertensive left ventricular hypertrophy. J Hypertens 1993; 11: 1097-101.
4. Diez J, Laviades C. Insulin-like growth factor I and collagen type III synthesis in patients with essential hypertension and left ventricular hypertrophy. J Hum Hypertens 1994; 8 (Suppl 1): S21-25.
5. Diez J, Laviades C, Martinez E, Gil MJ, Monrealt I, Monreal I. Insulin-like growth factor binding proteins in arterial hypertension: relationship to left ventricular hypertrophy. J Hypertens 1995; 13: 349-55.
6. Guler HP, Scmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 1989; 86: 2868-72.
7. Hussain MA, Schmitz O, Mengel A, et al. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation and enhances insulin sensitivity in humans. J Clin Invest 1993; 92: 2249-56.
8. Hussain MA, Schmitz O, Mengel A, et al. Comparison of effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth-hormone deficient humans. J Clin Invest 1994; 94: 1126-33.
9. Sara VR, Hall K. The insulin-like growth factors and their binding proteins. Physiol Rev 1990; 70: 591-614.
10. Brismar K, Gutniak M, Povoa G, Werner S, Hall K. Insulin regulates the 35 kDa IGF-I binding protein in patients with diabetes mellitus. J Endocrinol Invest 1988; 11: 599-602.
11. Brismar K, Hall K. Clinical applications of IGFBP-1 and its regulation. Growth Regul 1993; 3: 98-100.
12. Hall K, Brismar K, Degerblad M, et al. Serum levels of 25k IGF binding protein and their regulation. In: Drop SLS, Hintz RL, eds. Insulin-like growth factor binding proteins. Amsterdam: Elsevier, 1989: 21-6.
13. Taylor AM, Dunger DB, Preece MA, et al. The growth hormone independent insulin-like growth factor-I binding protein BP28 is associated with serum insulin-like growth factor-I inhibitory bioactivity in adolescent insulin-dependent diabetes. Clin Endocrinol 1990; 32: 229-39.
14. Brismar K, Hilding A, Lindgren B. Regulation of IGFBP-1 in humans. Growth Regul 1996: 449-56.
15. Baxter RC, Cowell CT. Diurnal rhythm of growth hormone independent binding protein for insulin-like growth factors in human plasma. J Clin Endocrinol Metab 1987; 65: 432-40.
16. Degerblad M, Póvoa G, Thorén M, Wivall IL, Hall K. Diurnal rhythm of 35 kD insulin-like growth factor binding protein in healthy subjects and patients with Cushing's disease. Acta Endocrinol 1989; 120: 5540-5.
17. Brismar K, Grill V, Eféndic S, Hall K. The insulin-like growth factor binding protein-1 in low and high insulin responders before and during dexamethasone treatment. Metabolism 1991; 40: 728-32.
18. Hilding A, Brismar K, Degerblad M, Thorén M, Hall K. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J Clin Endocrinol Metab 1995; 80: 2646-52.
19. Hellenius M-L, Brismar K, Berglund B, de Faire U. Effects on glucose tolerance, insulin secretion, insulin-like growth factor-I and its binding protein IGFBP-I in a randomized controlled diet and exercise study in healthy middle-aged men. J Int Med 1995; 238: 121-30.
20. Lemne C, Efendic S, Hamsten A, de Faire U. Impaired glucose and insulin metabolism in borderline hypertension. Blood Pressure 1994; 3: 287-94.
21. Lemne C, Lindvall K, Georgiades S, Fredriksson M, de Faire U. Structural cardiac changes in relation to 24-hour ambulatory blood pressure levels in borderline hypertension. J Int Med 1995; 238: 49-57.
22. Bang P, Eriksson U, Sara V, Wivall IL, Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determination in acid ethanol extracts by use of truncated IGF-I as radioligand. Acta Endocrinol 1991; 124: 620-9.
23. Povoa G, Roovete A, Hall K. Cross reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol 1984; 107: 563-70.
24. Carlsson K. Lipoprotein fractionation. J Clin Pathol 1973; 5 (Suppl 26): 32-7.
25. Hamsten A, Walldius G, Dahlén G, Johansson B, de Faire U. Serum lipoproteins and apolipoproteins in young male survivors of myocardial infarction. Atherosclerosis 1986; 59: 223-35.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
27. Harshfield GA, Pickering TG, Blank S, Lindahl C, Strand L, Larragh JH. A validation study of the Del Mar Avionics ambulatory blood pressure system. Ambul Electrocardiogr 1979; 1: 7-12.
28. Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 1222-30.
29. Hammond IW, Devereux RB, Alderman MH, Laragh JH. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults. J Am Coll Cardiol 1988; 12: 996-1004.
30. Mosteller RD. Letter. N Engl J Med 1987; 317: 1098.
31. Hollenbeck CB, ChenN, Chen Y-DI. Relationship between the plasma insulin response to oral glucose and insulin-stimulated glucose utilization in normal subjects. Diabetes 1984; 33: 460-4.
32. Nygren J, Samman M, Malm M, et al. Disturbed anabolic hormonal patterns in burned patients - the relation to glucagon. Clin Endocrinol 1995; 43: 491-500.
33. Bang P, Brismar K, Rosenfeld RG, Hall K. Fasting affects serum insulin-like growth factors (IGFs) and IGF binding proteins differently in patients with NIDDM versus healthy non-obese and obese, weight matched subjects. J Clin Endocrinol Metab 1994; 78: 960-7.
34. Berglund L, Lithell H. Prediction models for insulin resistance. Blood Pressure 1996; 5: 274-7.
35. Gibson JM, Westwood M, Young RJ, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996; 81: 860-3.
36. Östman-Smith I. Cardiac sympathetic nerves are the final common pathway in the induction of adaptive cardiac hypertrophy. Clin Sci 1981; 61: 265-72.
37. Schelling P, Fischer H, Ganten D. Angiotension and cell growth: a link to cardiovascular hypertrophy. J Hypertens 1991; 9: 3-15.
38. Naftilan AJ, Pratt RE, Dzau VJ. Angiotensin II induction of C-FOC, c-MYC and platelet derived growth factor in vascular smooth cells (Abstract 0592). In: Abstracts 12th Scientific Meeting of the International Society of Hypertension, Kyoto, Japan 1988.